Erasca, Inc. (ERAS)
| Market Cap | 3.72B +977.1% |
| Revenue (ttm) | n/a |
| Net Income | -277.02M |
| EPS | -0.96 |
| Shares Out | 310.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,143,949 |
| Open | 13.08 |
| Previous Close | 13.27 |
| Day's Range | 11.81 - 13.27 |
| 52-Week Range | 1.21 - 24.28 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 20.30 (+69.59%) |
| Earnings Date | May 11, 2026 |
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ERAS stock is "Buy." The 12-month stock price target is $20.3, which is an increase of 69.59% from the latest price.
News
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a ...
Erasca upgraded to Neutral from Underperform at BofA
BofA upgraded Erasca (ERAS) to Neutral from Underperform with a price target of $16, up from $9. The firm says the investor debate is now shifting from whether ERAS-0015 works…
Erasca Transcript: Jefferies Global Healthcare Conference 2026
Two lead RAS-targeting agents are advancing in phase I trials, with ERAS-0015 showing strong response rates in NSCLC and promising early data in pancreatic and colorectal cancers. Safety and durability profiles are favorable, and key data updates are expected next year.
Erasca to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...
Erasca Transcript: Bank of America Global Healthcare Conference 2026
ERAS-0015 shows strong efficacy and safety in key cancers, with expansion cohorts enrolling and combination studies underway. The company is advancing both pan-RAS and pan-KRAS programs, prioritizing combinations and capital efficiency to address high unmet needs in lung, pancreatic, and colorectal cancers.
Erasca price target lowered to $26 from $28 at Mizuho
Mizuho lowered the firm’s price target on Erasca (ERAS) to $26 from $28 and keeps an Outperform rating on the shares.
Erasca reports Q1 EPS (60c), consensus (23c)
“We continue to execute well across our RAS-targeting franchise, advancing ERAS-0015 clinical development ahead of schedule,” said Jonathan Lim, Erasca’s (ERAS) chairman, CEO, and co-founder. “The bes...
Erasca Reports First Quarter 2026 Business Updates and Financial Results
Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targ...
Erasca Earnings release: Q1 2026
Erasca released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Erasca Quarterly report: Q1 2026
Erasca has published its Q1 2026 quarterly earnings report on May 11, 2026.
Erasca enters AURORAS-1 clinical trial pact, supply agreement with Merck
Erasca (ERAS) announced a clinical trial collaboration and supply agreement with Merck (MRK). This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glu...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in...
Erasca to Present at the Bank of America Securities Health Care Conference
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...
Erasca recent share selloff overdone, says JPMorgan
JPMorgan analyst Anupam Rama believes the recent weakness in shares of Erasca (ERAS) is overdone. ERAS-0015 has potential for safety differentiation and looks efficacious in non-small cell lung cancer...
Erasca Slides: Corporate presentation
Erasca has posted slides in relation to its latest quarterly earnings report, which was published on April 30, 2026.
H.C. Wainwright sees pressure for Erasca shares pending safety visibility
H.C. Wainwright kept a Buy rating on Erasca (ERAS) with a $20 price target after the company reported preliminary Phase 1 data for ERAS-0015. The data show a “clear step-up…
Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.
Erasca is developing a competitor to Revolution Medicines' daraxonrasib.
Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ: ERAS). The investigation focuses on Erasca's execut...
Erasca falls after disclosing patient died after withdrawing from trial
In a regulatory filing, Erasca (ERAS) noted that the company announced “positive” preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tu...
Erasca Proxy statement: Proxy filing
Erasca filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Erasca Proxy statement: Proxy filing
Erasca filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Erasca price target raised to $9 from $2 at BofA
BofA raised the firm’s price target on Erasca (ERAS) to $9 from $2 and keeps an Underperform rating on the shares. Following “highly-anticipated” data for ERAS0015, the firm thinks ERAS-0015…
Erasca shares sink after patient death in early-stage cancer drug trial
Erasca shares fell over 35% before the bell on Tuesday after the company disclosed a patient death in an early-stage trial of its experimental cancer drug, even though analysts said the incident was...